Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung damage after COVID: how do patients heal?

NCT ID NCT04505631

Knowledge-focused Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study followed 332 adults who were hospitalized with severe COVID-19 pneumonia and needed oxygen. Researchers used CT scans and breathing tests to check for lasting lung damage. The goal was to understand how the lungs recover after a serious infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

332 people

The number who actually took part.

Started

Jun 2020

Finished

Jan 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who have been hospitalized for severe pneumonia due to SARS-CoV-2 infection will be seen in consultation at approximately 3 and 6 months after hospital discharge, as per standard practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age ≥ 18 years old * SARS-CoV-2 infection proven by RT-PCR and/or retrospective serology and/or a COVID-19 syndrome with evocative chest CT scan * Hospitalized for severe pneumonia due to SARS-CoV-2 infection requiring oxygen supply Exclusion criteria: * Not hospitalized for a severe COVID-19 infection * Absence of respiratory symptoms at V1 (3 months after hospital discharge), defined as: absence of residual exertional dyspnea and persistent pulmonary infiltrates on follow-up chest radiography at 1 month (if available), transcutaneous oxyhemoglobin saturation \>94% and normal pulmonary auscultation * Patient with pre-existing chronic lung disease prior to the first episode of COVID-19: chronic obstructive pulmonary disease confirmed by respiratory function testing with a forced expiratory volume in one second (FEV1) \< 50% and/or a diffusing capacity for carbon monoxide (DLCO) \< 60%, fibrotic lung disease or chronic respiratory failure (on long-term oxygen therapy) * Opposition to participation in the study * Patient under legal protection * Patient not affiliated to/beneficiary of a social security scheme

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 Dyspnea lung disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 Dyspnea

Contacts and locations

Locations

  • Centre Hospitalier Annecy Genevois

    Metz-Tessy, France

  • Centre Hospitalier Colmar

    Colmar, France

  • Centre Hospitalier Douai

    Douai, France

  • Centre Hospitalier Départemental Vendée - La Roche sur Yon

    La Roche-sur-Yon, France

  • Centre Hospitalier Le Raincy Montfermeil

    Montfermeil, France

  • Centre Hospitalier Métropole Savoie

    Chambéry, France

  • Centre Hospitalier Robert Boulin - Libourne

    Libourne, France

  • Centre Hospitalier Régional Metz-Thioville

    Metz, France

  • Centre Hospitalier Régional Orléans

    Orléans, France

  • Centre Hospitalier de Dunkerque

    Dunkirk, France

  • Centre Hospitalier de Soissons

    Soissons, France

  • Centre Hospitalier de la Côte Basque - Bayonne

    Bayonne, France

  • Centre Hospitalier du Mans

    Le Mans, France

  • Groupe Hospitalier de Mulhouse et de la Région Sud-Alsace

    Mulhouse, Alsace, 68100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.